Evidence map›Paper›PMID 26754533›Full record

ArticleLeukemia & lymphoma2016

The leukemic oncoprotein NPM1-RARA inhibits TP53 activity.

Erin M Swaney, Anuja Chattopadhyay, Irina Abecassis, Elizabeth A Rush, Robert L Redner

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Leukemia & lymphoma, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact, top 99% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Erin M Swaneya Department of Medicine , University of Pittsburgh, and University of Pittsburgh Cancer Institute, University of Pittsburgh , Pittsburgh , PA , USA.
Anuja Chattopadhyaya Department of Medicine , University of Pittsburgh, and University of Pittsburgh Cancer Institute, University of Pittsburgh , Pittsburgh , PA , USA.
Irina Abecassisa Department of Medicine , University of Pittsburgh, and University of Pittsburgh Cancer Institute, University of Pittsburgh , Pittsburgh , PA , USA.
Elizabeth A Rusha Department of Medicine , University of Pittsburgh, and University of Pittsburgh Cancer Institute, University of Pittsburgh , Pittsburgh , PA , USA.
Robert L Rednera Department of Medicine , University of Pittsburgh, and University of Pittsburgh Cancer Institute, University of Pittsburgh , Pittsburgh , PA , USA.
UPMC Hillman Cancer Center · US

Funding

VECTOR CORE FACILITYP30CA047904 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI JOHN C. BYRD · 1988 to 2026
$158.0M
Characterization of a Novel Translocation Product in APLR01CA067346 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI REDNER, ROBERT L · 2006 to 2009
$914k
NCI NIH HHS P30 CA047904NCI NIH HHS R01 CA067346
6 · The paper itself

Abstract

The variant acute promyelocytic leukemia (APL) translocation t(5;17)(q35;q21) fuses the N-terminus of nucleophosmin (NPM1) to the retinoic acid receptor alpha (RARA). We found that ectopic NPM1-RARA expression decreased TP53 protein levels in target cells. NPM1-RARA impaired TP53-dependent transcription. Cells expressing NPM1-RARA were more resistant to apoptotic stimuli. This work identifies the TP53 tumor suppressor as a novel target through which NPM1-RARA impacts leukemogenesis, and confirms the importance of impairment of TP53 in establishment of the APL phenotype.

Indexed as

AnimalsApoptosisCarcinogenesisChlorocebus aethiopsChromosomes, Human, Pair 17Chromosomes, Human, Pair 5COS CellsHumansLeukemia, Promyelocytic, AcuteNuclear ProteinsNucleophosminOncogene Proteins, FusionRetinoic Acid Receptor alphaTranslocation, GeneticTumor Suppressor Protein p53U937 CellsNPM1 protein, humanNuclear ProteinsNucleophosminOncogene Proteins, FusionRARA protein, humanRetinoic Acid Receptor alphaTP53 protein, humanTumor Suppressor Protein p53Acute promyelocytic leukemiaapoptosisNPM1-RARAnucleophosminTP53

Identifiers

PMID26754533
PMCPMC5023140
OpenAlexW2301784324

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.